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Abstract: We have developed a one-pot, tandem 
Sonogashira/Suzuki–Miyaura coupling reaction, which is unknown 
synthetically, and applied it for the synthesis of a library of potential 
natural ligand nonmimetic inhibitors of the lipid-transfer protein, 
ceramide-transport protein (CERT). The characteristic feature of this 
reaction is that the two-step coupling reaction proceeds smoothly 
with only 5 mol% of palladium catalyst. Furthermore, the location of 
the formed carbon–carbon bond would be strictly defined because of 
the difference in reactivity. Therefore, many derivatives could be 
synthesized in high yields without the formation of regioisomeric 
byproducts by the same procedure. We also performed a semi-gram 
scale synthesis of several derivatives to provide the bioactive assey. 
After synthesizing as many as 113 derivatives, we identified a 
nonnatural mimetic inhibitor with activity comparable to that of the 
known inhibitor (1R,3S)-HPA-12. 
Introduction 
Lipids are the principal constituents of all cell membranes and 
play important roles in its function and organelle structure. Lipid-
transfer proteins mediate interorganelle transport of membrane 
lipids at organelle contact sites in cells, playing fundamental 
roles in the lipidome and membrane biogenesis in eukaryotes.[1] 
The ceramide-transport protein (CERT) carries ceramide from 
the endoplasmic reticulum to the Golgi apparatus, converting it 
into the phosphosphingolipid, sphingomyelin.[2] CERT was 
demonstrated to be a key player in the homeostasis of the 
ceramide–sphingomyelin axis of the cellular lipidome and has 
several advantages as a model lipid-transfer protein for the 
development of novel inhibitors with a rational strategy.[3]
We previously developed a ceramide-mimetic compound, 
(1R,3S)-HPA-12, as a potent inhibitor of CERT.[4,5] (1R,3S)-HPA-
12 binds to a ceramide-binding pocket in CERT, thereby acting 
as a competitive antagonist, whereas it does not affect the 
ceramide-metabolizing enzymes.[6] Nevertheless, natural ligand-
mimetic compounds may directly bind not only to the desired 
target, but also to various undesired targets sharing the same 
natural ligand. Therefore, we started the development of a series 
of small chemicals with no apparent ceramide mimicry, but with 
potent inhibitory activity of the function of CERT in human 
cultured cells. Cocrystallographic structures of the ceramide-
binding of CERT with multiple types of ceramide species have 
been solved.[7] After an in silico virtual screening of ca. 3 ´ 106 
compounds for protein–chemical compound docking 
(calculations were performed by Daiich Sankyo RD Novare Co. 
Ltd., Tokyo, Japan), we identified one candidate, hereafter 
referred to as seed compound 1 (SC1), which has no obvious 
ceramide-like structure (Figure 1).[8] 
Figure 1. The structure of C16-ceramide, (1R,3S)-HPA-12, and seed 
compound 1. 
A surface plasmon resonance (SPR) assay, which is a 
quantitative assay system that can be used to determine the 
physical affinity of low-molecular-weight chemicals for CERT, 
revealed that that the binding constant of SC1 was 
approximately 400 times weaker than that of (1R,3S)-HPA-12.[8] 
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predicted hydrogen-bonding network between SC1 and the 
ceramide-binding pocket in the cocrystal complex. Based on 
these results, we considered that SC1 was a promising initial 
compound for the development of a natural ligand-nonmimetic 
inhibitor of CERT. 
Synthetic strategy 
For the systematic expansion of SC1 derivatives, the structural 
backbone of the target compound needed to be simple but 
amenable to modification through combinatorial synthesis. 
Judging from the cocrystal complex of SC1 with the CERT 
protein,[8] the terminal hydroxyethanesulfonyl group of SC1 was 
expected to be crucial for the formation of a hydrogen-bonding 
network to several amino acids of the ceramide-binding pocket 
in the CERT protein in a similar mode to the natural ligand 
ceramide. However, although the pyrazole unit has no 
hydrogen-bonding interaction to the CERT protein, it may work 
as a “hinge” for the structure of SC1. The 2-pyridyl group, 
another terminal group of SC1, did not participate in any clear 
interaction at this stage. For ease of synthesis, we next 
attempted to find more simplified compounds before 
constructing diverse sets of SC-derivatives. For this purpose, we 
replaced the pyrazole moiety with a simple hydrocarbon so that 
it we could focus on the role of the “hinge” in the new CERT 
inhibitors. To allow hydrogen bonding between the CERT 
inhibitor at two different locations of the amino acids of the 
CERT protein, the “hinge” is required to separate the rigid parts 
of the structure by an appropriate distance and with optimal 
conformation. Therefore, we set the hydrocarbon derivatives 
CºC (2), C−C (3), trans C=C (4), cis C=C (5), or cyclopropyl (6 
for cis and 7 for trans) groups as the “hinge” structure (Figure 2). 
 
Figure 2. The structure of the target compounds 2–7. 
Since it was expected that compounds 3–7 could be easily 
derived from the corresponding precursor 2 in either one or two 
steps, it was desirable to synthesize the series of compounds 2 
on a gram scale and to convert them into the target compounds 
3–7 (Scheme 1). The 2 series would be converted into the 3 
series by catalytic hydrogenative reduction by using our 
developed palladium catalyst.[9] However, the 4 or 5 series 
would be synthesized by E/Z selective partial reduction from the 
2 series with a palladium catalyst.[10] The 7 or 6 series would be 
converted through the cyclopropanation of the 4 or 5 series, 
respectively, through an improved modification of the Simons–
Smith reaction.[11] 
 
Scheme 1. The target CERT inhibitor candidates 2–7 and their retrosynthetic 
strategy. 
Results and Discussion 
It was envisioned that the compound 2 series could be 
synthesized by connecting the units in stages by using 
Sonogashira[12,13] and Suzuki–Miyaura coupling.[14] First, we 
examined the Sonogashira coupling reaction, which tends to 
proceed under milder conditions than the Suzuki–Miyaura 
coupling. The combination of commercially available 8a and 9a 
gave the corresponding target product 11a in only 13% yield 
(Scheme 2, top). No improvement was found when pinacol ester 
9b was used instead of 9a (Scheme 2, bottom). 
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2.5 eq. NEt3, 45 oC or 60 oC ; no reaction
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When the reaction was carried out with 9c[12b,c] in an effort to 
improve the reactivity, the reaction proceeded smoothly even at 
room temperature, and the corresponding compound 11c was 
obtained in high yield (95%).[12b] To conduct the Suzuki–Miyaura 
coupling reaction of 11c with “right-side” unit 10a[15] for the next 
step, we tried to synthesize 11a by boration of 11c; however, the 
yield was extremely low (Scheme 3, top). Although the boration 
of the “right-side” unit 10a was examined so that coupling with 
11c could be performed, the desired reaction did not proceed. 
Several nucleophilic reactions of nBuLi to 10a might proceed to 
give a complex mixture. The same tendency was observed in 
the case of boration of 10c, which was silyl-protected 10a. In this 
case, contained the silicon rearranged complex compounds 
were also seem like formed (Scheme 3, bottom). 
 
Scheme 3. Attempted derivatization of each unit for the Suzuki–Miyaura 
coupling. 
Based on the finding that the Sonogashira coupling reaction 
using aryl iodide proceeded smoothly, and that the borylation of 
10a, 10c, and 11c failed, we conducted the Sonogashira 
coupling reaction with 9d, which has higher reactivity than 9a or 
9b as a substrate. The reaction itself proceeded successfully; 
however, the target compound 11b was difficult to isolate. 
Finally, 11b was isolated in 60% yield by using water-containing 
deactivated neutral silica gel (Scheme 4). 
 
Scheme 4. The optimized Sonogashira coupling. 
Given that both the Sonogashira and Suzuki–Miyaura coupling 
reactions use a palladium catalyst, we envisioned that a one-pot 
tandem reaction may proceed in which the palladium catalyst 
would be used for both coupling reactions, which is also 
effective in green chemistry. To our knowledge, there are only 
two examples of such one-pot tandem Sonogashira/Suzuki–
Miyaura coupling reactions[16] to provide biaryl acetylene 
compounds,[17] such as 2, without addition of any palladium 
catalyst at the second-step coupling reaction.[18] Indeed, after the 
Sonogashira coupling reaction under the conditions already 
described in Scheme 4, we added the “right-side” unit 10c with 
base and additional solvents continuously, and then the mixture 
was heated. Interestingly, the TBDMS group of primary alcohol 
could not withstand under the reaction conditions (100 ˚C in 
aqueous DMF with potassium carbonate) and desilylated 
desired three-component coupling compound 2a was obtained 
in 51% yield as the main product. Compare with the 11b as an 
intermediate in the reaction mixture, compound 2a was stable 
and could be purified easily using conventional neutral silica gel. 
The three-component coupling reaction could also be conducted 
with unprotected 10a to give 2a directly in 83% yield (Scheme 5). 
 
Scheme 5. Developed one-pot tandem Sonogashira/Suzuki–Miyaura coupling 
reactions for the synthesis of 2a. 
With these optimized conditions in hand, 2a–v were synthesized 
by combinations of various “left-side” units 8a–d, central units 
9d–r and 10a, and further derivatizations were performed to 
synthesize 3a–v, 4a–v, 5a–v, 6a–v, and 7m, respectively (Table 
1).[8] As noted previously, the characteristic feature of this three-
component, one-pot tandem coupling reaction is that the two-
step coupling reaction proceeds smoothly with only 5 mol% of 
palladium catalyst. Furthermore, the location of the formed 
carbon–carbon bond would be strictly defined because of the 
difference in reactivity: i.e., one is the terminal acetylene–aryl 
iodine and the other is aryl boron–aryl bromine. Therefore, even 
compounds such as 2m–v could be synthesized in high yields 
without the formation of regioisomeric byproducts, which would 
be expected to be difficult to separate by column 
chromatography. 
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with 10c (R = SitBuMe2): 51%
with 10a (R = H): 83%




 Coupling Yield to 2 (%) Yield of 2 to 3 (%) Yield of 2 to 4 (%) Yield of 2 to 5 (%) Yield of 5 to 6 (%) Yield of 4 to 7 (%) 
a 83 quant. 34 (2a 60) 15 (2a 79) 10 (5a 57) - 
b (R5 = F) 77 94 89 80 27 (5b 15) - 
c (R2 = Me) 77 94 51 (3c 26) 81 25 (5c 62) - 
d (R2 = Me, R5 = F) 83 94 65 89 29 (5d 40) - 
e (R4 = tBu) 78 44 (2e 43) 80 (2e 2) 79 30 (5e 33) - 
f (R4 = Me) 84 62 (2f 32) 90 39 (2f 32) 79 - 
g (R4 = CF3) 68 88 (2g 2) 69 61 (3g 4) NR - 
h (R3 = Me) 68 81 70 (2h 10) 47 (3h 30) 56 (5h 19) - 
i (R1 = Me) 89 80 29 (2i 69) 56 11 (5i 70) - 
j (R2 = R3 = Me) 64 89 67 (3j 13) 60 (2j 23, 3j 5) 70 - 
k (R1 = R3 = Me) 73 76 58 (2k 41) 35 (2k 38, 3k 6) 32 (5k 30) - 
l (R5 = Me) 66 76 (2l 23) 97 70 56 - 
m (R3 = nPr) 57 93 59 22 69 8 (4m 61) 
n (R3 = nC5H11) 65 77 (2n 11) 48 (2n 25) 77 (2n 4) 62 (5n 20) - 
o (R3 = iPr) 39 33 (2o 36) 53 70 (2o 24) 8 (5o 68) - 
p (R3 = iBu) 52 38 (2p 50) 50 64 (2p 30) NR - 
q (R1 = Me, R3 = nPr) 70 89 49 (2q 47) 14 (4q 77) 4 (5q 79) - 
r (R1 = nC5H11, R3 = nPr) 76 quant. 38 (2r 59) 7 (2r 20, 4r 73) 10 (5r 78) - 
s (R3 = nC7H15) 71 96 57 29 (4s 67) 72 - 
t (R3 = nC8H17) 78 89 55 62 (4t 37) 41 - 
u (R3 = cC6H11) 44 82 71 82 (4u 15) 73 (5u 17) - 
v (R3 = cC5H9) 69 81 59 70 (4v 18) 74 (5v 16) - 
[a] For all compounds, R1 = R2 = R3 = R4 = R5 = H unless otherwise specified. The yields of recovered starting materials or isolated by-products are shown in 
parentheses. 
The coupling reactions generally proceeded smoothly with high 
yields, except for 2o, 2p, and 2u, which have bulky substituents 
at R3. Alkynes 2 were easily converted into alkanes 3 by 
hydrogenation. For the synthesis of trans-alkenes 4 and cis-
alkenes 5, the reactions were relatively clean with some 
recovery of the starting materials. Furthermore, even under cis-
selective conditions, thermodynamically stable trans-alkenes 4q 
or 4r were obtained predominantly when 5q or 5r were used as 
substrates. Although not examined in detail, neither 6g nor 6p 
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conditions. When the same cyclopropanation conditions used for 
cis derivatives were applied for the synthesis of trans-
cyclopropane 7m from 4m, the yield of the desired product was 
only 8%, with 61% recovered starting material. In fact, given that 
the SPR activity of 7m was lower than that of 6m, we did not 
optimize the reaction conditions for the synthesis of other 
derivatives of the 7 series. 
The SPR activity of the 113 derivatives thus synthesized was 
examined,[19] and it was found that 6n was a potent inhibitor. We 
then conducted a 0.5 to 1.0 g scale synthesis of 6n (see 
Experimental section). Although 6n was synthesized as a 
racemate, we conducted optical resolution by chiral HPLC 
column chromatography, and it was revealed that the (1S,2R)-
isomer had almost the same binding constant with CERT protein 
as that of (1R,3S)-HPA-12 based on the SPR assay. X-ray 
crystallographic analysis of a cocrystal of (1S,2R)-6n and CERT 
revealed that the cyclopropane ring of 6n played the expected 
role of a "hinge." As we also anticipated, the 2-pyridyl group of 
6n participated in hydrogen bonding with an amino acid within 
the CERT protein. This new hydrogen bond, which did not exist 
in the case of SC1, might strongly assist the ability of 6n to 
function as an antagonist of CERT. Moreover, the n-pentyl group 
in the central unit of 6n seems to have a suitable hydrophobic 
interaction that enables it to fit the hydrophobic pocket of the 
CERT protein. 
Conclusions 
We have developed a one-pot, tandem Sonogashira/Suzuki–
Miyaura coupling reaction, which is unknown synthetically, and 
applied it for the synthesis of a library of potential natural ligand 
nonmimetic inhibitors of a lipid-transfer protein, CERT. The 
characteristic feature of this three-component, one-pot tandem 
coupling reaction is that the two-step coupling reaction proceeds 
smoothly with only 5 mol% palladium catalyst. After synthesizing 
as many as 113 derivatives, a non-natural mimetic inhibitor was 
identified that had an activity comparable to that of the known 
inhibitor (1R,3S)-HPA-12. 
Experimental Section 
Details of the synthetic procedures used to obtain the compounds listed 
in Table 1, and the starting materials, together with 1H and 13C NMR 
spectra of synthesized compounds, are available from the generalist 
repository figshare (DOI: 10.6084/m9.figshare.7398533). Here, we will 
describe the gram-scale synthesis of compound 2n and its derivatization 
to 3n–6n as a typical experimental procedure. We also present the 
characterization data for compounds 10c and 11b, which were not 
previously reported as intermediates under investigation or in routes not 
achieved. 
Gram-scale synthesis of 2n: A 50 mL single-necked round-bottom flask 
equipped with stirring bar and reflux condenser was flame-dried under 
vacuum, and then charged with Ar. To this flask, copper iodide (6.0 mol%, 
46.7 mg, 0.240 mmol), 3-iodo-4-pentylbenzeneboronic acid pinacol ester 
(9m) (1.60 g, 4.00 mmol), and bis(triphenylphosphine)palladium(II) 
dichloride (5.0 mol%, 141 mg, 0.200 mmol), triethylamine (11.2 mL), and 
2-ethynylpyridine (8a) (1.1 eq., 0.436 mL, 4.40 mmol) were added 
successively. After stirring at room temperature for 12 hours, DMF (16.0 
mL), water (4.00 mL), 4-hydroxyethylsulfonylbromobenzene (10a) (1.2 
eq., 1.17 g, 4.80 mmol), and potassium carbonate (2.0 eq., 1.15 g, 8.00 
mmol) were added successively and the resulting reaction mixture was 
stirred and heated at 100 °C for 12 hours. After cooling, the mixture was 
diluted with water (10 mL) and ethyl acetate (10 mL) filtered over a 
Celite® pad, and the organic phase was separated. The aqueous layer 
was extracted with ethyl acetate (3 ´ 20 mL) and the combined organic 
layer was washed with water (2 ´ 50 mL) and brine (2 ´ 50 mL), and 
dried over anhydrous Na2SO4. The solvent was evaporated in vacuo and 
the residue was purified by silica gel column chromatography 
(hexane/ethyl acetate, 1:1, v/v), to give 4'-(2-hydroxyethanesulfonyl)-4-
pentyl-3-(pyridin-2-ylethynyl)-1,1'-biphenyl (2n) (1.13 g, 65%). 1H-NMR 
(CDCl3) d: 8.65 (1H, d, J = 4.1 Hz), 7.99 (2H, d, J = 8.7 Hz), 7.86 (1H, d, 
J = 1.8 Hz), 7.79 (2H, d, J = 8.2 Hz), 7.71 (1H, td, J = 7.8, 1.8 Hz), 7.54 
(2H, td, J = 5.3, 2.7 Hz), 7.37 (1H, d, J = 7.8 Hz), 7.27 (1H, ddd, J = 7.7, 
4.9, 1.3 Hz), 4.05 (2H, dd, J = 11.0, 6.4 Hz), 3.40 (2H, dd, J = 7.1, 3.9 
Hz), 2.94 (2H, t, J = 7.8 Hz), 2.89 (1H, t, J = 6.4 Hz), 1.75 (2H, dd, J = 
15.1, 7.3 Hz), 1.43–1.38 (4H, m), 0.90 (3H, t, J = 7.1 Hz). 13C-NMR 
(CDCl3) d: 14.0, 22.5, 30.3, 31.6, 34.3, 56.4, 58.4, 87.5, 92.5, 122.6, 
122.9, 127.2, 127.8, 127.8, 128.6, 129.7, 131.6, 136.2, 136.4, 137.5, 
143.4, 145.9, 146.2, 150.2; HRMS (m/z): [M+H]+ calcd. for C26H28NO3S: 
434.17899; found: 434.17957. 
Derivatization from 2n to 3n:[9] Pd/PMPSi-Al2O3 (5.0 mol%, 74.1 mg, Pd 
0.099 mmol g-1), 2n (63.6 mg, 0.1467 mmol) and ethanol (2.0 mL) were 
added to a 30 mL pear-shaped single-necked flask with stirring bar. H2 
gas (balloon) was introduced into the reaction vessel and the contents of 
the flask was stirred for 12 h. The reaction mixture was filtered through a 
Celite® pad then washed with ethyl acetate (10 mL). The solvent was 
evaporated in vacuo and the residue was purified by preparative PTLC 
(hexane/ethyl acetate, 1:2, v/v, twice), to give 4'-(2-
hydroxyethanesulfonyl)-4-pentyl-3-(pyridin-2-ylethyl)-1,1'-biphenyl (3n) 
(49.5 mg, 77%) together with recovered starting material (7.1 mg, 11%). 
1H NMR (CDCl3) d: 8.58 (1H, t, J = 2.5 Hz), 7.95 (2H, t, J = 4.1 Hz), 7.70 
(2H, t, J = 4.4 Hz), 7.59 (1H, td, J = 7.6, 1.8 Hz), 7.39 (2H, t, J = 4.8 Hz), 
7.27 (1H, t, J = 3.7 Hz), 7.15 (1H, td, J = 6.2, 1.1 Hz), 7.09 (1H, d, J = 7.8 
Hz), 4.04 (2H, s), 3.40 (2H, dd, J = 6.9, 4.1 Hz), 3.29 (1H, s), 3.12 (4H, 
ddd, J = 14.4, 8.0, 4.4 Hz), 2.67 (2H, t, J = 7.8 Hz), 1.61 (2H, dd, J = 15.6, 
7.3 Hz), 1.38 (4H, dd, J = 7.1, 3.4 Hz), 0.91 (3H, t, J = 7.1 Hz). 13C NMR 
(CDCl3) d: 14.0, 22.5, 30.8, 31.8, 32.3, 32.8, 39.7, 56.3, 58.4, 121.3, 
123.0, 125.0, 127.7, 128.3, 130.0, 136.3, 136.4, 136.9, 140.0, 141.7, 
147.0, 149.3, 161.0. HRMS (m/z): [M+H]+ calcd. for C26H32NO3S: 
438.21029; found: 438.20928. 
Derivatization from 2n to 4n:[10] An oven-dried 10 mL glass tube 
containing a stirring bar was charged with Pd2(dba)3·CHCl3 (2.0 mol%, 
4.3 mg, 4.15 µmol), dppb (4.0 mol %, 3.7 mg, 8.70 µmol) and (2n) (86.3 
mg, 0.199 mmol). The tube was sealed and then evacuated and 
backfilled with Ar. Dioxane (0.6 mL) was subsequently injected and, after 
stirring the mixture at room temperature for 15 min, aqueous HCO2H 
(25%; 48 µL, 1.3 eq., 0.26 mmol) was added. The reaction was heated to 
80 °C for 2 h, then further aqueous HCO2H (25%; 48 µL, 1.3 eq., 0.26 
mmol) was added. The mixture was heated at 80 °C for another 8 h, then 
filtered through a Celite® pad, and washed with ethyl acetate (10 mL). 
The solvent was evaporated in vacuo and the residue was purified by 
column chromatography (hexane/ethyl acetate, 1:2, v/v), to give (E)-4'-(2-
hydroxyethanesulfonyl)-4-pentyl-3-(pyridin-2-yl-2vinyl)-1,1'-biphenyl (4n) 
(41.8 mg, 48%) together with recovered starting material (21.5 mg, 25%). 
1H NMR (CDCl3) d: 8.62 (1H, d, J = 4.1 Hz), 7.99 (2H, d, J = 8.7 Hz), 7.93 
(1H, d, J = 15.6 Hz), 7.88 (1H, d, J = 1.8 Hz), 7.81 (2H, d, J = 8.7 Hz), 
7.69 (1H, td, J = 7.8, 1.8 Hz), 7.48 (1H, dd, J = 7.8, 1.8 Hz), 7.43 (1H, d, 
J = 8.2 Hz), 7.31 (1H, d, J = 8.2 Hz), 7.16 (2H, dd, J = 13.7, 9.2 Hz), 4.04 
(2H, d, J = 5.5 Hz), 3.41 (2H, t, J = 5.5 Hz), 3.18 (1H, s), 2.84 (2H, t, J = 
7.8 Hz), 1.65 (2H, dd, J = 15.1, 7.3 Hz), 1.38 (4H, t, J = 3.7 Hz), 0.90 (3H, 
t, J = 7.1 Hz). 13C NMR (CDCl3) d: 14.0, 22.4, 30.7, 31.6, 33.0, 56.3, 58.4, 
122.0, 122.2, 125.0, 126.9, 127.8, 128.5, 129.9, 130.2, 130.5, 136.1, 
136.6, 136.8, 137.2, 142.1, 146.8, 149.7, 155.5. HRMS (m/z): [M+H]+ 
calcd. for C26H30NO3S: 436.19464; found: 436.19137. 
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Gram-scale synthesis of 5n from 2n:[10] An oven-dried 10 mL glass 
tube containing a stirring bar was charged with Pd2(dba)3·CHCl3 (2.0 
mol%, 49.7 mg, 48.0 µmol), dppb (8.0 mol%, 82.0 mg, 192 µmol) and 2n 
(1045.4 mg, 2.41 mmol). The tube was sealed and then evacuated and 
backfilled with Ar, then dioxane (2.4 mL) was subsequently injected. After 
stirring the mixture at room temperature for 15 min, HCO2H (98%; 189 µL, 
2.0 eq. 4.80 mmol) was added. The mixture was heated at 80 °C for 15 h, 
then filtered through a Celite® pad, and washed with ethyl acetate (20 
mL). The solvent was evaporated in vacuo and the residue was purified 
by column chromatography (hexane/ethyl acetate, 1:1 to 1:2, v/v), to give 
(Z)-4'-(2-hydroxyethanesulfonyl)-4-pentyl-3-(pyridin-2-yl-2-vinyl)-1,1'-
biphenyl (4n) (805.3 mg, 77%) together with recovered starting material 
(46.4 mg, 4%). 1H NMR (CDCl3) d: 8.57 (1H, d, J = 4.1 Hz), 7.88 (2H, d, J 
= 8.7 Hz), 7.52 (2H, d, J = 8.7 Hz), 7.46 (1H, dd, J = 8.0, 2.1 Hz), 7.36 
(3H, td, J = 9.8, 4.0 Hz), 7.07 (1H, t, J = 6.2 Hz), 6.99 (2H, dd, J = 14.7, 
10.1 Hz), 6.84 (1H, d, J = 12.4 Hz), 4.00 (2H, t, J = 5.7 Hz), 3.36 (3H, t, J 
= 5.5 Hz), 2.69 (2H, t, J = 7.8 Hz), 1.63 (2H, t, J = 7.6 Hz), 1.35 (4H, dd, J 
= 7.3, 3.7 Hz), 0.89 (3H, t, J = 7.1 Hz). 13C NMR (CDCl3) δ: 13.9, 22.4, 
30.1, 31.6, 33.3, 56.2, 58.3, 121.8, 123.6, 126.5, 127.5, 128.3, 128.4, 
130.2, 131.7, 132.1, 135.6, 136.2, 136.5, 137.1, 142.0, 146.4, 149.4, 
155.9. HRMS (m/z): [M+H]+ calcd. for C26H30NO3S: 436.19464; found: 
436.19450. 
Semi-gram-scale synthesis of 6n from 5n:[11] Anhydrous CH2Cl2 (9.2 
mL) was added to a solution of diethylzinc (1.1 M in hexanes, 5.0 eq., 8.4 
mL, 9.24 mmol) under Ar atmosphere. The solution was cooled in an ice 
bath and a solution of trifluoroacetic acid (5.0 eq., 708 µL, 9.24 mmol) in 
anhydrous CH2Cl2 (4.6 mL) was then added dropwise very slowly into the 
reaction mixture by using a syringe. After stirring for 15 min, a solution of 
CH2I2 (5.0 eq., 744 µL, 9.24 mmol) in anhydrous CH2Cl2 (4.6 mL) was 
added. After an additional 20 min of stirring, a solution of 5n (805.3 mg, 
1.85 mmol) in anhydrous CH2Cl2 (4.6 mL) was added. After stirring for 1 
h at 0 °C, the ice bath was removed, and the mixture was stirred until the 
reaction was complete. The reaction was quenched with saturated 
aqueous NH4Cl and CH2Cl2 (10 mL), and the layers were separated. The 
aqueous layer was extracted with CH2Cl2 (2 ´ 20 mL), and the combined 
organic layers were washed with saturated NaHCO3 (50 mL), and brine 
(50 mL), and then dried over Na2SO4, filtered, concentrated in vacuo, and 
purified by column chromatography (hexane/ethyl acetate, 1:1, v/v), to 
give cis-4'-(2-hydroxyethanesulfonyl)-4-pentyl-3-(2-(pyridin-2-yl) 
cyclopropyl)-1,1'-biphenyl (6n) (515.4 mg, 62%) together with recovered 
starting material (163.8 mg, 20%). 1H NMR (CDCl3) d: 8.28 (1H, dq, J = 
5.0, 0.9 Hz), 7.94 (2H, dt, J = 8.5, 2.0 Hz), 7.65 (2H, dt, J = 8.8, 1.9 Hz), 
7.35 (1H, d, J = 1.9 Hz), 7.29 (2H, tt, J = 10.3, 3.4 Hz), 7.08 (1H, t, J = 
4.0 Hz), 6.89 (1H, ddd, J = 7.3, 4.9, 1.0 Hz), 6.74 (1H, t, J = 4.0 Hz), 
4.04-4.02 (2H, m), 3.39 (2H, td, J = 4.1, 2.3 Hz), 3.25 (1H, br s), 2.80-
2.69 (2H, m), 2.63 (1H, dd, J = 16.0, 8.8 Hz), 2.55-2.48 (1H, m), 1.92-
1.88 (1H, m), 1.63-1.51 (2H, m), 1.45-1.27 (5H, m), 0.90 (3H, dd, J = 9.0, 
5.1 Hz). 13C NMR (CDCl3) δ: 11.4, 14.0, 22.5, 24.4, 25.8, 29.7, 31.8, 32.2, 
56.3, 58.4, 120.5, 121.9, 125.0, 127.6, 128.3, 128.6, 128.9, 135.2, 135.3, 
135.8, 136.9, 144.0, 147.1, 148.3,158.4. HRMS (m/z): [M+H]+ calcd. for 
C27H32NO3S: 450.21029; found: 450.20989. 
Preparation of 10c: A 10 mL two-necked round-bottom flask equipped 
with a stirring bar was flame-dried under vacuum and then charged with 
Ar. To this flask, 10a (1.3336 g, 5.0 mmol) and imidazole (0.4085 g, 6.0 
mmol), and then dry DMF (5.0 mL) were added successively. After 
stirring at room temperature to dissolved all materials, then the reaction 
mixture was cool to at 0 ˚C. tButyldimethylsilyl chloride (0.829 g, 5.5 
mmol) dissolved in 5.0 mL of dry DMF was added via syringe then 
stirring for 4 hours. The reaction mixture was quenched with water (20 
mL) and ethyl acetate (20 mL), and the layers were separated. The 
aqueous layer was extracted with ethyl acetate (2 ´ 10 mL), and the 
combined organic layers were washed with water (30 mL), and brine (30 
mL), and then dried over Na2SO4, filtered, concentrated in vacuo, and 
purified by column chromatography (hexane/ethyl acetate, 9:1, v/v), to 
give 10c (1.8244 g, 96%). 1H NMR (CDCl3) d: 7.77 (2H, dd, J = 8.5, 2.3 
Hz), 7.68 (2H, dd, J = 8.5, 2.3 Hz), 4.01–3.98 (2H, m), 3.34–3.33 (2H, m), 
0.76 (9H, s), –0.05 (6H, s). 13C NMR (CDCl3) d: 139.2, 132.4, 129.7, 
128.9, 59.0, 57.1, 25.6, 18.0, –5.7. 
Preparation of 11b: A 10 mL two-necked round-bottom flask equipped 
with a stirring bar was flame-dried under vacuum and then charged with 
Ar. To this flask, copper iodide (6.0 mol%, 4.6 mg, 0.024 mmol), 3-
iodobenzeneboronic acid pinacol ester (9d) (132.1 mg, 0.40 mmol), and 
bis(triphenylphosphine)palladium(II) dichloride (5.0 mol%, 14.0 mg, 0.020 
mmol), triethylamine (1.13 mL), and 2-ethynylpyridine (8a) (1.1 eq., 
0.0444 mL, 0.44 mmol) were added successively. After stirring at room 
temperature for 24 hours, diluted with diethyl ether (5 mL), then filtered 
over a Celite® pad with diethyl ether (20 mL). The filtrate was washed 
with water (2 ´ 20 mL) and brine (1 ´ 20 mL), and then dried over 
anhydrous Na2SO4. The solvent was evaporated in vacuo and the 
residue was purified by deactivated silica gel (prepared by addition of 10 
mL of water to 20 g of dry neutral silica-gel then stir until smooth) column 
chromatography (hexane/ethyl acetate, 4:1, v/v), to give 11b (43.1 mg, 
60%). 1H NMR (CDCl3) d: 8.62 (1H, d, J = 4.0 Hz), 8.09 (1H, s), 7.80 (1H, 
dd, J = 7.4, 1.1 Hz), 7.68 (2H, td, J = 6.4, 4.5 Hz), 7.51 (1H, d, J = 7.4 
Hz), 7.38 (1H, t, J = 7.7 Hz), 7.28–7.22 (1H, m), 1.35 (12H, s). 13C NMR 
(CDCl3) d: 150.0, 143.4, 138.6, 136.1,135.0, 134.4, 127.7, 127.1, 122.7, 
121.7, 89.3, 88.6, 84.0, 24.8. 
Chiral Separation of 6n: An experimental condition for the resolution of 
6n by chiral HPLC has been reported in Supplemental METHOD of ref.8. 
Both enantiomers of 6n were separated by CHIRALPAK® IA-3 (Daicel 
Corporation, 4.6 mm id. x 250 mm length) as a chiral column. The 
absolute configuration of each enantiomer was determined by X-ray co-
crystallography of CERT protein with each compound (see Fig. 5 in ref. 
8). After separation, we measured the optical rotation of each samples. 
(+)-(1S,2R)-6n: HPLC (hexane:iPrOH, 6:4, v/v, flow rate = 1.0 ml min-1, 
UV detection at 254 nm) tR = 6.7 min.; [a]D33.3 = +109.0 (c 1.32, CHCl3) 
(–)-(1R,2S)-6n: HPLC (hexane:iPrOH, 6:4, v/v, flow rate = 1.0 ml min-1, 
UV detection at 254 nm) tR = 9.5 min.; [a]D33.8 = –106.5 (c 1.26, CHCl3) 
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